518044-35-4

Usage

Uses

Used in Pharmaceutical Industry:
Mal-PEG2-t-butyl ester is used as a PEGylation agent for improving the solubility, stability, and bioavailability of therapeutic proteins and peptides. The presence of the maleimide group enables selective conjugation to thiol-containing biomolecules, facilitating targeted drug delivery and reducing potential side effects.
Used in Drug Delivery Systems:
In the field of drug delivery, Mal-PEG2-t-butyl ester serves as a versatile linker for the development of novel drug conjugates. Its ability to form covalent bonds with thiol groups allows for the creation of stable and controlled-release drug systems, enhancing the efficacy and safety of various therapeutic agents.
Used in Bioconjugation:
Mal-PEG2-t-butyl ester is utilized as a bioconjugation agent, allowing for the covalent attachment of PEGylated moieties to proteins, peptides, or other biomolecules with thiol groups. This modification can improve the pharmacokinetic properties of these biomolecules, such as circulation time, reduced immunogenicity, and enhanced solubility.
Used in Diagnostics:
In the diagnostics industry, Mal-PEG2-t-butyl ester can be employed to create PEGylated contrast agents or imaging probes. The PEGylation can enhance the stability and biocompatibility of these agents, potentially improving their performance in various diagnostic applications, such as magnetic resonance imaging (MRI) or optical imaging.

Upstream product

• 55750-48-6 N-methoxycarbonylmaleimide 
• 252881-74-6 tert-butyl 3-(2-(2-(2-aminoethoxyl)ethoxy)ethoxy)propanoate 

Downstream Products

• 518044-40-1 3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoic acid 

Relevant academic research and scientific papers

Development of a library of N-substituted maleimides for the local functionalization of linear polymer chains

A novel kinetic process was investigated for functionalizing ondemand local regions of well-defined linear polystyrene chains. This concept relies on the atom transfer radical copolymerization (ATRP) of functional N-substituted maleimides with styrene. This copolymerization is a controlled radical process, which combines two unique kinetic features: i) all the polymers chains are growing simultaneously and ii) the cross-propagation of the comonomers is highly-favored as compared to homopolymerization. Thus, discrete amounts of N-substituted maleimides (e.g., 1 equiv as compared to initiator) are consumed extremely fast in the copolymerization process and are therefore locally incorporated in narrow regions of the growing polystyrene chains. MALDI-TOF analysis of model copolymers indicated that this kinetic concept is efficient. Although a sequence distribution is observed, well-defined polymer chains having only one or two functional maleimide units per chain were found to be the most abundant species. Furthermore, the position of the functional groups in the polystyrene chains can be kinetically-controlled by adding the N-substituted maleimides at desired times during the course of the polymerization. This method is very versatile and can be applied to a wide variety of N-substituted maleimides. Herein, a library of 20 different maleimides bearing various functional groups (e.g., aromatic moieties, fluorinated groups, hydroxy functions, protected esters, protected amines, light-responsive moieties, fluorophores and biorelevant functions such as short poly(ethylene glycol) segments or biotin moieties) was investigated. In most cases, the functional N-substituted maleimides could be efficiently incorporated in the polystyrene chains.

ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS

The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.